Literature DB >> 7781660

Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia.

H J Blom1, H A Kleinveld, G H Boers, P N Demacker, H L Hak-Lemmers, M T Te Poele-Pothoff, J M Trijbels.   

Abstract

The pathobiochemical mechanism of arteriosclerosis in hyperhomocysteinaemia has not yet been elucidated. In vitro studies have shown that the cytotoxic properties of homocysteine can be ascribed to its generation of reactive oxygen species. We studied lipid peroxidation, both in vivo and in vitro, in 10 homozygous cystathionine synthase-deficient (CSD) patients and in a control group of 10 healthy subjects of comparable age and sex. The susceptibility of low-density lipoprotein (LDL) from hyperhomocysteinaemic patients to oxidation was determined in vitro by continuously measuring the conjugated diene production induced by incubation with copper ions. Oxidation resistance (expressed as lag time), maximal oxidation rate, and extent of oxidation (expressed as total diene production) of LDL from CSD patients were not significantly different from those of LDL from controls. Furthermore, the time needed to reach maximal diene production, i.e. t(max), was similar for LDL from patients and controls. In addition, the vitamin E concentrations in LDL of CSD patients and controls were similar. The mean concentration (+/- SD) of plasma thiobarbituric acid reactive substances (TBARS), an indicator of in vivo lipid peroxidation, was 2.2 +/- 0.7 mumol L-1 in CSD patients, a lower value than that measured in the matched controls (5.0 +/- 2.0 mumol L-1). Investigation of in vivo and in vitro parameters of lipid peroxidation shows that the increased risk of arteriosclerosis in hyperhomocysteinaemia is unlikely to be due to increased lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781660     DOI: 10.1111/j.1365-2362.1995.tb01541.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Reversible pulmonary arterial hypertension in cobalamin-dependent cobalamin C disease due to a novel mutation in the MMACHC gene.

Authors:  Mehmet Gündüz; Filiz Ekici; Eda Özaydın; Serdar Ceylaner; Belen Perez
Journal:  Eur J Pediatr       Date:  2014-05-24       Impact factor: 3.183

Review 2.  Putative mechanisms for vascular damage by homocysteine.

Authors:  M F Bellamy; I F McDowell
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

3.  Allicin improves carotid artery intima-media thickness in coronary artery disease patients with hyperhomocysteinemia.

Authors:  De-Shan Liu; Shu-Li Wang; Jun-Mei Li; Er-Shun Liang; Ming-Zhong Yan; Wei Gao
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

4.  Low doses of eicosapentaenoic acid, docosahexaenoic acid, and hypolipidemic eicosapentaenoic acid derivatives have no effect on lipid peroxidation in plasma.

Authors:  H Vaagenes; Z A Muna; L Madsen; R K Berge
Journal:  Lipids       Date:  1998-11       Impact factor: 1.880

5.  Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia.

Authors:  Neetu Tyagi; Alexander V Ovechkin; David Lominadze; Karni S Moshal; Suresh C Tyagi
Journal:  J Cell Biochem       Date:  2006-08-01       Impact factor: 4.429

6.  The effect on endothelial function of vitamin C during methionine induced hyperhomocysteinaemia.

Authors:  C G Hanratty; L T McGrath; D F McAuley; I S Young; D G Johnston
Journal:  BMC Cardiovasc Disord       Date:  2001-06-27       Impact factor: 2.298

7.  Relationship between Diabetic Retinopathy and Subclinical Hypothyroidism: a meta-analysis.

Authors:  Jingyang Wu; Song Yue; Jin Geng; Limin Liu; Weiping Teng; Lei Liu; Lei Chen
Journal:  Sci Rep       Date:  2015-07-20       Impact factor: 4.379

8.  Guanxinkang Decoction Exerts Its Antiatherosclerotic Effect Partly through Inhibiting the Endoplasmic Reticulum Stress.

Authors:  Hao Wang; Zhi-Min Zheng; Bu-Lang Gao
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-18       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.